At what age can nasal decongestants (NDs) be used in pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nasal Decongestant Use in Pediatric Patients: Age Guidelines

Nasal decongestants should not be used in children under 6 years of age due to significant safety concerns including documented fatalities, and should only be used with caution in children 6 years and older. 1, 2

Age-Specific Recommendations

Children Under 6 Years

  • Oral decongestants (such as pseudoephedrine) should not be used in children under 6 years of age due to safety concerns including agitated psychosis, ataxia, hallucinations, and even death 1
  • Between 1969 and 2006, there were 54 fatalities associated with decongestants in children under 6 years, with 43 of these deaths occurring in infants under 1 year 1, 2
  • FDA-approved labeling for pseudoephedrine explicitly states "do not use this product in children under 6 years of age" 3
  • Controlled trials have shown that antihistamine-decongestant combination products are not effective for children in this age group 1, 2

Children 6-11 Years

  • Oral decongestants can be used in children 6 years and older but only at appropriate doses and with careful monitoring 1
  • For pseudoephedrine, the FDA-approved dosing for children 6-11 years is 1 tablet every 4-6 hours, not to exceed 4 tablets in 24 hours 3
  • Topical nasal decongestants like oxymetazoline are FDA-approved for children 6 years and older with adult supervision, using 2-3 sprays in each nostril no more often than every 10-12 hours, not exceeding 2 doses in 24 hours 4

Children 12 Years and Older

  • Children 12 years and older can follow adult dosing guidelines for both oral and topical decongestants 4, 3
  • For pseudoephedrine, this is 2 tablets every 4-6 hours, not exceeding 8 tablets in 24 hours 3

Safety Considerations

Topical Nasal Decongestants

  • Topical decongestants should be used for no more than 3 days to avoid rhinitis medicamentosa (rebound congestion) 1
  • Topical vasoconstrictors require particular caution in children under 1 year (if used at all) due to the narrow margin between therapeutic and toxic doses 1, 5
  • Potential adverse effects include local stinging, burning, sneezing, and dryness of the nose and throat 1
  • Rare but serious cerebrovascular adverse events have been reported, including anterior ischemic optic neuropathy, stroke, and vascular headache 1, 6

Oral Decongestants

  • Even at recommended doses, oral decongestants may cause stimulatory effects resulting in tachyarrhythmias, insomnia, and hyperactivity in children 1, 2
  • These effects are especially concerning when combined with other stimulant medications, such as those used for ADHD management 1, 2
  • Phenylephrine, which has replaced pseudoephedrine in many OTC products, has not been well established as an effective oral decongestant 1

Alternative Options for Young Children

  • Saline nasal irrigation is a safe and modestly effective option for nasal congestion in children of all ages 2, 7
  • Second-generation antihistamines (cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine) have good safety profiles in young children for allergic rhinitis 1, 2
  • Intranasal corticosteroids are the most effective medications for controlling symptoms of allergic rhinitis and can be considered for appropriate cases 1, 2

Common Pitfalls to Avoid

  • Administering adult formulations or doses to children 2
  • Using multiple cold/cough products simultaneously, which can lead to overdose 1, 2
  • Continuing topical decongestants beyond 3 days, which can lead to rhinitis medicamentosa 1
  • Assuming that OTC status means a medication is completely safe for all ages 2, 8
  • Using phenylephrine as a substitute for pseudoephedrine without recognizing its limited oral efficacy 1

The evidence clearly shows that the risks of nasal decongestants in children under 6 years outweigh the benefits, and caution should be exercised even in older children 1, 2, 9, 10.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Safety of Chlorpheniramine Maleate + Phenylephrine in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Nasal Drops in Children and Infants: Safety Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants.

European annals of otorhinolaryngology, head and neck diseases, 2015

Research

Nasal decongestants for the common cold.

The Cochrane database of systematic reviews, 2004

Research

Nasal decongestants in monotherapy for the common cold.

The Cochrane database of systematic reviews, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.